CHICAGO HIGHLIGHTS 2024 – GU ROUNDTABLE DISCUSSION: Prostate
OR
Chair
Dr. Christian Kollmannsberger
Panelists
Dr. Lucia Nappi
Dr. Vishal Navani
Studies/trials discussed:
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
- CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer.
- LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer
- CCTG PR21: A randomized phase II study of [177lu]lu-PSMA-617 verus docetaxel in patients with metastatic castration-resistant prostate cancer and PSMA-positive disease (NCT04663997).
